vs
ALLURION TECHNOLOGIES, INC.（ALUR）与GLAUKOS Corp（GKOS）财务数据对比。点击上方公司名可切换其他公司
GLAUKOS Corp的季度营收约是ALLURION TECHNOLOGIES, INC.的39.6倍（$143.1M vs $3.6M）。GLAUKOS Corp净利率更高（-93.4% vs -167.0%，领先73.6%）。GLAUKOS Corp同比增速更快（35.7% vs -35.4%）。过去两年GLAUKOS Corp的营收复合增速更高（29.3% vs -38.0%）
罗宾逊科技是一家日本电子游戏开发商，由塞思·罗宾逊创立。该公司开发了《赤龙传说》、《行星：太空探索》等BBS门户游戏，还与Hamumu Software合作开发了实验性多人创意沙盒游戏《成长国度》，该作于2013年在iOS、安卓、Windows和macOS平台推出。
Glaukos Corp是一家专注于眼科领域的医疗科技企业，开发并商业化用于治疗青光眼、角膜疾病等眼部病症的微创手术器械、处方药物及消费级产品，主要市场覆盖北美、欧洲及亚太地区，为全球医院、眼科诊所及患者提供服务。
ALUR vs GKOS — 直观对比
营收规模更大
GKOS
是对方的39.6倍
$3.6M
营收增速更快
GKOS
高出71.0%
-35.4%
净利率更高
GKOS
高出73.6%
-167.0%
两年增速更快
GKOS
近两年复合增速
-38.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $3.6M | $143.1M |
| 净利润 | $-6.0M | $-133.7M |
| 毛利率 | 44.5% | -1.1% |
| 营业利润率 | -174.2% | -97.7% |
| 净利率 | -167.0% | -93.4% |
| 营收同比 | -35.4% | 35.7% |
| 净利润同比 | 37.2% | -298.0% |
| 每股收益（稀释后） | $-0.69 | $-2.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALURGKOS
| Q4 25 | $3.6M | $143.1M | ||
| Q3 25 | $2.7M | $133.5M | ||
| Q2 25 | $3.4M | $124.1M | ||
| Q1 25 | $5.6M | $106.7M | ||
| Q4 24 | $5.6M | $105.5M | ||
| Q3 24 | $5.4M | $96.7M | ||
| Q2 24 | $11.8M | $95.7M | ||
| Q1 24 | $9.4M | $85.6M |
净利润ALURGKOS
| Q4 25 | $-6.0M | $-133.7M | ||
| Q3 25 | $-11.9M | $-16.2M | ||
| Q2 25 | $-9.3M | $-19.7M | ||
| Q1 25 | $-1.5M | $-18.1M | ||
| Q4 24 | $-9.6M | $-33.6M | ||
| Q3 24 | $8.7M | $-21.4M | ||
| Q2 24 | $-8.3M | $-50.5M | ||
| Q1 24 | $2.0M | $-40.8M |
毛利率ALURGKOS
| Q4 25 | 44.5% | -1.1% | ||
| Q3 25 | 49.1% | 78.4% | ||
| Q2 25 | 73.9% | 78.3% | ||
| Q1 25 | 74.6% | 77.2% | ||
| Q4 24 | 45.3% | 72.9% | ||
| Q3 24 | 58.0% | 76.6% | ||
| Q2 24 | 76.4% | 76.4% | ||
| Q1 24 | 73.2% | 76.3% |
营业利润率ALURGKOS
| Q4 25 | -174.2% | -97.7% | ||
| Q3 25 | -362.3% | -12.3% | ||
| Q2 25 | -205.7% | -18.3% | ||
| Q1 25 | -130.5% | -19.4% | ||
| Q4 24 | -306.2% | -27.2% | ||
| Q3 24 | -229.9% | -25.5% | ||
| Q2 24 | -79.4% | -31.3% | ||
| Q1 24 | -121.4% | -45.6% |
净利率ALURGKOS
| Q4 25 | -167.0% | -93.4% | ||
| Q3 25 | -447.1% | -12.2% | ||
| Q2 25 | -276.3% | -15.8% | ||
| Q1 25 | -26.9% | -17.0% | ||
| Q4 24 | -171.8% | -31.8% | ||
| Q3 24 | 162.8% | -22.1% | ||
| Q2 24 | -70.7% | -52.8% | ||
| Q1 24 | 21.3% | -47.7% |
每股收益（稀释后）ALURGKOS
| Q4 25 | $-0.69 | $-2.34 | ||
| Q3 25 | $-1.53 | $-0.28 | ||
| Q2 25 | $-1.28 | $-0.34 | ||
| Q1 25 | $-0.31 | $-0.32 | ||
| Q4 24 | $-3.22 | $-0.56 | ||
| Q3 24 | $3.40 | $-0.39 | ||
| Q2 24 | $-4.34 | $-1.00 | ||
| Q1 24 | $0.96 | $-0.82 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.4M | $90.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-77.2M | $656.2M |
| 总资产 | $15.8M | $893.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALURGKOS
| Q4 25 | $5.4M | $90.8M | ||
| Q3 25 | $6.1M | $98.2M | ||
| Q2 25 | $12.7M | $100.8M | ||
| Q1 25 | $20.4M | $114.3M | ||
| Q4 24 | $15.4M | $169.6M | ||
| Q3 24 | $28.7M | $100.1M | ||
| Q2 24 | $19.3M | $68.1M | ||
| Q1 24 | $29.7M | $42.5M |
股东权益ALURGKOS
| Q4 25 | $-77.2M | $656.2M | ||
| Q3 25 | $-82.9M | $769.5M | ||
| Q2 25 | $-64.0M | $765.1M | ||
| Q1 25 | $-69.8M | $764.0M | ||
| Q4 24 | $-78.0M | $766.9M | ||
| Q3 24 | $-64.8M | $668.5M | ||
| Q2 24 | $-70.6M | $665.2M | ||
| Q1 24 | $-66.2M | $450.7M |
总资产ALURGKOS
| Q4 25 | $15.8M | $893.5M | ||
| Q3 25 | $18.1M | $999.4M | ||
| Q2 25 | $28.2M | $987.0M | ||
| Q1 25 | $38.4M | $966.2M | ||
| Q4 24 | $32.8M | $974.8M | ||
| Q3 24 | $50.7M | $926.5M | ||
| Q2 24 | $46.5M | $919.7M | ||
| Q1 24 | $60.0M | $933.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.3M | $6.8M |
| 自由现金流经营现金流 - 资本支出 | — | $3.9M |
| 自由现金流率自由现金流/营收 | — | 2.7% |
| 资本支出强度资本支出/营收 | — | 2.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-22.5M |
8季度趋势，按日历期对齐
经营现金流ALURGKOS
| Q4 25 | $-5.3M | $6.8M | ||
| Q3 25 | $-6.5M | $-10.1M | ||
| Q2 25 | $-7.6M | $7.0M | ||
| Q1 25 | $-9.5M | $-18.5M | ||
| Q4 24 | $-13.3M | $507.0K | ||
| Q3 24 | $-11.5M | $-9.6M | ||
| Q2 24 | $-8.9M | $-18.4M | ||
| Q1 24 | $-8.6M | $-33.9M |
自由现金流ALURGKOS
| Q4 25 | — | $3.9M | ||
| Q3 25 | — | $-11.7M | ||
| Q2 25 | — | $5.8M | ||
| Q1 25 | — | $-20.5M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | $-11.5M | $-11.0M | ||
| Q2 24 | $-9.4M | $-20.5M | ||
| Q1 24 | $-8.7M | $-34.8M |
自由现金流率ALURGKOS
| Q4 25 | — | 2.7% | ||
| Q3 25 | — | -8.8% | ||
| Q2 25 | — | 4.7% | ||
| Q1 25 | — | -19.2% | ||
| Q4 24 | — | -1.2% | ||
| Q3 24 | -214.9% | -11.4% | ||
| Q2 24 | -79.6% | -21.4% | ||
| Q1 24 | -93.1% | -40.7% |
资本支出强度ALURGKOS
| Q4 25 | — | 2.0% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | 0.0% | 1.6% | ||
| Q3 24 | 1.3% | 1.5% | ||
| Q2 24 | 3.7% | 2.2% | ||
| Q1 24 | 1.1% | 1.1% |
现金转化率ALURGKOS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1.31× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -4.33× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALUR
暂无分部数据
GKOS
| Glaucoma | $86.4M | 60% |
| Other | $35.1M | 25% |
| Corneal Health | $21.6M | 15% |
